186 related articles for article (PubMed ID: 20857891)
1. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
Vamvakas EC
Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
[TBL] [Abstract][Full Text] [Related]
2. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
Pietersz RN
Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
[TBL] [Abstract][Full Text] [Related]
3. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
4. A critical comparison of platelet preparation methods.
Vassallo RR; Murphy S
Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
[TBL] [Abstract][Full Text] [Related]
5. Relative risk of reducing the lifetime blood donation deferral for men who have had sex with men versus currently tolerated transfusion risks.
Vamvakas EC
Transfus Med Rev; 2011 Jan; 25(1):47-60. PubMed ID: 21134626
[TBL] [Abstract][Full Text] [Related]
6. Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany.
Vamvakas EC; Hitzler WE
Clin Lab; 2013; 59(1-2):1-22. PubMed ID: 23505902
[TBL] [Abstract][Full Text] [Related]
7. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
8. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
Vasconcelos E; Figueiredo AC; Seghatchian J
Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
[TBL] [Abstract][Full Text] [Related]
9. Donor selection criteria to maximize double platelet products (DPP) by platelet apheresis.
Wollersheim J; Dautzenberg M; van de Griendt A; Sybesma B
Transfus Apher Sci; 2006 Apr; 34(2):179-86. PubMed ID: 16574489
[TBL] [Abstract][Full Text] [Related]
10. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States.
Kleinman S; Grossman B; Kopko P
Transfusion; 2010 Jun; 50(6):1312-21. PubMed ID: 20456690
[TBL] [Abstract][Full Text] [Related]
11. Platelet concentrates, from whole blood or collected by apheresis?
van der Meer PF
Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
[TBL] [Abstract][Full Text] [Related]
12. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
Schrezenmeier H; Seifried E
Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
[TBL] [Abstract][Full Text] [Related]
13. Donor exposures in recipients of pooled platelet concentrates: a case-study in arithmetic, logic, "expert opinion", and the "peer review" process.
Vamvakas EC; Hitzler WE
Clin Lab; 2013; 59(3-4):415-20. PubMed ID: 23724633
[TBL] [Abstract][Full Text] [Related]
14. Implementation of a strategy to prevent TRALI in a regional blood centre.
Insunza A; Romon I; Gonzalez-Ponte ML; Hoyos A; Pastor JM; Iriondo A; Hermosa V
Transfus Med; 2004 Apr; 14(2):157-64. PubMed ID: 15113380
[TBL] [Abstract][Full Text] [Related]
15. Automated platelet collection using the latest apheresis devices in an Indian setting.
Agarwal P; Verma A
Transfus Apher Sci; 2009 Oct; 41(2):135-8. PubMed ID: 19709930
[TBL] [Abstract][Full Text] [Related]
16. Use of random versus apheresis platelet concentrates.
Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
[TBL] [Abstract][Full Text] [Related]
17. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
Lozano ML; Rivera J; Vicente V
Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
[TBL] [Abstract][Full Text] [Related]
18. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks.
Vamvakas EC
Transfusion; 2009 Dec; 49(12):2743-58. PubMed ID: 19682339
[TBL] [Abstract][Full Text] [Related]
19. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
20. [Quality of thrombocyte preparations from buffy coat or platelet-rich plasma].
Bux J; Müller K; Misterek J; Mueller-Eckhardt C
Beitr Infusionsther; 1990; 26():99-102. PubMed ID: 1703912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
